The pharmaceutical biggie GlaxoSmithKline announced its proposed launch of final clinical trials for an anti-malaria vaccine in seven African countries to kick-off in January.
"This is the most advanced vaccine, and the only one today that has been shown effective against malaria in infants and children in Africa," said Joe Cohen, who created the vaccine after two decades of work for GlaxoSmithKline.
Malaria
Malaria is caused by a parasite that enters blood through the bite of an infected mosquito. It is characterized by fever, vomiting, shivering, sweating and other symptoms.
Advertisement
Studies in Mozambique on children under five found that the vaccine, called RTS,S, was 30-35 percent effective against benign cases of malaria and 50 percent effective against severe cases, over a period of about three years.
"With 30-35 percent effectiveness, that would prevent 100 million cases of illness a year ... and suggests that several million lives could be saved," Cohen told AFP, noting that malaria spells death for nearly one million children every year.
![Mosquito Diseases]( "Mosquito Diseases")
Mosquito-borne diseases, like malaria, filaria, dengue, etc are common in places conducive of mosquito breeding. Swamps, ponds and stagnated drainage provide optimal breeding ground for mosquitoes.
In Mozambique, the vaccine also reduced the number of hospitalizations from malaria, said Christian Loucq, director of the Malaria Vaccine Initiative, which is financed in part by the Bill et Melinda Gates Foundation.
The clinical trials will take place at 11 sites in Kenya, Malawi, Mozambique, Gabon, Ghana, Burkina Faso et Tanzania.
About 16,000 children will take part in the study, which includes African scientists, and the first trials should begin in January in some countries, Loucq said.
"This is a vaccine designed to activate the immune system in such a way ... that it destroys the parasite very quickly when it is in the blood or the liver, before it reaches the red blood cells," Cohen explained.
The phase III trial, the last step before seeking regulatory approval, would allow sales of the vaccine possibly in 2012, if the results are conclusive.
Developing the vaccine has cost some 500 million dollars i.e. 392 millions euros, Cohen and Loucq said.
Source: AFP
TAN
Mosquito Diseases
Mosquito-borne diseases, like malaria, filaria, dengue, etc are common in places conducive of mosquito breeding. Swamps, ponds and stagnated drainage provide optimal breeding ground for mosquitoes.
Advertisement
In Mozambique, the vaccine also reduced the number of hospitalizations from malaria, said Christian Loucq, director of the Malaria Vaccine Initiative, which is financed in part by the Bill et Melinda Gates Foundation.
The clinical trials will take place at 11 sites in Kenya, Malawi, Mozambique, Gabon, Ghana, Burkina Faso et Tanzania.
About 16,000 children will take part in the study, which includes African scientists, and the first trials should begin in January in some countries, Loucq said.
"This is a vaccine designed to activate the immune system in such a way ... that it destroys the parasite very quickly when it is in the blood or the liver, before it reaches the red blood cells," Cohen explained.
The phase III trial, the last step before seeking regulatory approval, would allow sales of the vaccine possibly in 2012, if the results are conclusive.
Developing the vaccine has cost some 500 million dollars i.e. 392 millions euros, Cohen and Loucq said.
Source: AFP
TAN
Waterborne Disease - Animation
Interactive section of Medindia gives details regarding waterborne disease
Advertisement
 Study Says Massive Fall in Malaria Cases in Gambia Sets Model for AfricaIncidence of malaria in Gambia has plunged thanks to an array of low-cost strategies, offering the tempting vision of eliminating this disease in parts of Africa, a study published | Advertisement
|
Advertisement
Recommended Readings
Latest Tropical Disease News
The Ministry of Health (MoH) in Cambodia has reported the first Zika virus case in the country since 2016.
The WHO has assessed the risk of monkeypox for the general population in countries not previously impacted by the current outbreak as low.
Nipah is a zoonotic virus, meaning it can be transmitted from animals to humans. Fruit bats serve as the natural reservoirs for Nipah virus.
Nipah Virus (NiV) or Hendra virus is a deadly virus that spreads via contact with the saliva, urine, or excreta of fruit bats or pigs.
Nipah virus is mainly a zoonotic disease, transferring from animals to humans, and can also spread via contaminated food or contact with infected individuals.
